.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,474,995

« Back to Dashboard

Claims for Patent: 5,474,995

Title: Phenyl heterocycles as cox-2 inhibitors
Abstract:The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases, ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
Inventor(s): Ducharme; Yves (Montreal, CA), Gauthier; Jacques Y. (Laval, CA), Prasit; Petpiboon (Kirkland, CA), Leblanc; Yves (Kirkland, CA), Wang; Zhaoyin (Pierrefond, CA), Leger; Serge (Dollard Des Ormeaux, CA), Therien; Michel (Laval, CA)
Assignee: Merck Frosst Canada, Inc. (Kirkland, CA)
Application Number:08/179,467
Patent Claims: 1. A compound of the formula XXXIII ##STR216## or a pharmaceutically acceptable salt thereof wherein: R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3,

(b) S(O).sub.2 NH.sub.2,

(c) S(O).sub.2 NHC(O)CF.sub.3,

(d) S(O)(NH)CH.sub.3,

(e) S(O)(NH)NH.sub.2,

(f) S(O)(NH)NHC(O)CF.sub.3,

(g) P(O)(CH.sub.3)OH, and

(h) P(O)(CH.sub.3)NH.sub.2,

R.sup.2 is selected from the group consisting of

(a) C.sub.1-6 alkyl,

(b) C.sub.3, C.sub.4, C.sub.5, C.sub.6, and C.sub.7, cycloalkyl,

(c) mono-, di- or tri-substituted phenyl wherein the substituent is selected from the group consisting of

(1) hydrogen,

(2) halo,

(3) C.sub.1-6 alkoxy,

(4) C.sub.1-6 alkylthio,

(5) CN,

(6) CF.sub.3,

(7) C.sub.1-6 alkyl,

(8) N.sub.3,

(9) --CO.sub.2 H,

(10) --CO.sub.2 --C.sub.1-4 alkyl,

(11) --C(R.sup.5)(R.sup.6)--OH,

(12) --C(R.sup.5)(R.sup.6)--O--C.sub.1-4 alkyl, and

(13) --C.sub.1-6 alkyl--CO.sub.2 --R.sup.5 ;

(d) mono-, di- or tri-substituted heteroaryl wherein the heteroaryl is a monocyclic aromatic ring of 5 atoms, said ring having one hetero atom which is S, O, or N, and optionally 1, 2, or 3 additional N atoms; or

the heteroaryl is a monocyclic ring of 6 atoms, said ring having one hetero atom which is N, and optionally 1, 2 or 3 additional N atoms; said substituents are selected from the group consisting of

(1) hydrogen,

(2) halo, including fluoro, chloro, bromo and iodo,

(3) C.sub.1-6 alkyl,

(4) C.sub.1-6 alkoxy,

(5) C.sub.1-6 alkylthio,

(6) CN,

(7) CF.sub.3,

(8) N.sub.3,

(9) --C(R.sup.5)(R.sup.6)--OH,

(10) --C(R.sup.5)(R.sup.6)--O--C.sub.1-4 alkyl;

R.sup.5 and R.sup.6 are each independently selected from the group consisting of

(a) hydrogen,

(b) C.sub.1-6 alkyl,

or R.sup.5 and R.sup.6 together with the carbon to which they are attached form a monocyclic saturated carbon ring of 3, 4, 5, 6 or 7 atoms.

2. A compound according to claim 1 wherein

R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3,

(b) S(O).sub.2 NH.sub.2,

(c) S(O).sub.2 NHC(O)CF.sub.3,

(d) S(O)NHCH.sub.3,

(e) S(O)NHNH.sub.2, and

(f) S(O)NHNHC(O)CF.sub.3 ;

R.sup.2 is selected from the group consisting of

(a) C.sub.1-4 alkyl,

(b) C.sub.3, C.sub.4, C.sub.5, C.sub.6, and C.sub.7, cycloalkyl,

(c) mono- or di-substituted phenyl wherein the substituent is selected from the group consisting of

(1) hydrogen,

(2) fluoro, chloro, and bromo,

(3) C.sub.1-4 alkoxy,

(4) C.sub.1-4 alkylthio,

(5) CN,

(6) CF.sub.3,

(7) C.sub.1-4 alkyl,

(8) N.sub.3,

(9) --CO.sub.2 H,

(10) --CO.sub.2 --C.sub.1-3 alkyl,

(11) --C(R.sup.5)(R.sup.6)--OH, and

(12) --C(R.sup.5)(R.sup.6)--O--C.sub.1-3 alkyl.

3. A compound according to claim 2 wherein

R.sup.2 is selected from the group consisting of

(a) cyclohexyl, and

(b) mono- or di-substituted phenyl, and wherein the substitutents are selected from the group consisting of

(1) hydrogen,

(2) halo,

(3) C.sub.1-4 alkoxy,

(4) C.sub.1-4 alkylthio,

(5) CN,

(6) CF.sub.3,

(7) C.sub.1-4 alkyl,

(8) N.sub.3, and

(9) --C(R.sup.5)(R.sup.6)--OH;

R.sup.5 and R.sup.6, are each independently selected from the group consisting of

(a) hydrogen,

(b) methyl or ethyl, or R.sup.5 and R.sup.6 together with the carbon to which they are attached form a saturated carbon ring of 4, 5 or 6 atoms.

4. A compound according to claim 3 wherein

R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3,

(b) S(O).sub.2 NH.sub.2,

(c) S(O)NHCH.sub.3, and

(d) S(O)NHNH.sub.2 ;

R.sup.2 is selected from the group consisting of mono or di-substituted phenyl wherein the substitutents are selected from the group consisting of

(1) hydrogen,

(2) halo, selected from the group consisting of fluoro, chloro and bromo,

(3) C.sub.1-3 alkoxy,

(4) C.sub.1-3 alkylthio,

(5) CN, and

(6) C.sub.1-3 alkyl.

5. A compound according to claim 4 wherein

R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3,

(b) S(O).sub.2 NH.sub.2,

(c) S(O)NHCH.sub.3, and

(d) S(O)NHNH.sub.2 ;

R.sup.2 is mono or di-substituted phenyl wherein the substitutents are selected from the group consisting of

(1) hydrogen,

(2) halo, selected from the group consisting of fluoro, chloro and bromo,

(3) methoxy, and

(4) methyl.

6. A compound according to claim 5 wherein

R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3, and

(b) S(O).sub.2 NH.sub.2,

R.sup.2 is mono or di-substituted phenyl wherein the substitutents are selected from the group consisting of

(1) hydrogen,

(2) halo, selected from the group consisting of fluoro, chloro and bromo.

7. A compound according to claim 2 wherein

R.sup.2 is a mono- or di-substituted heteroaryl wherein heteroaryl is selected from the group consisting of

(1) furanyl,

(2) diazinyl, triazinyl, tetrazinyl,

(3) imidazolyl,

(4) isooxazolyl,

(5) isothiazolyl,

(6) oxadiazolyl,

(7) oxazolyl,

(8) pyrazolyl,

(9) pyrrolyl,

(10) thiadiazolyl,

(11) thiazolyl,

(12) thienyl,

(13) triazolyl, and

(14) tetrazolyl,

wherein the substitutents are selected from the group consisting of

(a) hydrogen,

(b) fluoro or chloro,

(c) C.sub.1-3 alkoxy,

(d) C.sub.1-6 alkylthio,

(e) CN,

(5) CF.sub.3,

(6) C.sub.1-3 alkyl,

(7) --C(R.sup.5)(R.sup.6)--OH;

(8) --C(R.sup.5)(R.sup.6)--O--C.sub.1-4 alkyl.

8. A compound according to claim 7 wherein

R.sup.2 is a mono- or di-substituted heteroaryl wherein heteroaryl is selected from the group consisting of

(1) 2-furanyl,

(2) 3-furanyl,

(3) 2-thienyl,

(4) 3-thienyl,

(5) 3-isoxazolyl,

(6) 4-isoxazolyl,

(7) 5-isoxazolyl,

(8) 3-isothiazolyl,

(9) 4-isothiazolyl,

(10) 5-isothiazolyl,

(11) 2-oxazolyl,

(12) 4-oxazolyl,

(13) 5-oxazolyl,

(14) 2-thiazolyl,

(15) 4-thiazolyl,

(16) 5-thiazolyl,

(17) 1,2,3-thiadiazol-4-yl,

(18) 1,2,3-thiadiazol-5-yl,

(19) 1,2,4-thiadiazol-3-yl,

(20) 1,2,4-thiadiazol-5-yl,

(21) 1,3,4-thiadiazol-2-yl,

(22) 1,2,5-thiadiazol-3-yl,

(23) 1,2,3-oxadiazol-4-yl,

(24) 1,2,3-oxadiazol-5-yl,

(25) 1,2,4-oxadiazol-3-yl,

(26) 1,2,4-oxadiazol-5-yl,

(27) 1,3,4-oxadiazol-2-yl,

(28) 1,2,5-oxadiazol-3-yl,

(29) pyrazol-4-yl,

(30) pyrazol-5-yl,

(31) 1,2,3-triazol-4-yl,

(32) 1,2,3-triazol-5-yl,

(33) 1,2,4-triazol-3-yl,

(34) 1,2,4-triazol-5-yl,

(35) 1,2-diazinyl,

(36) 1,3-diazinyl,

(37) 1,4-diazinyl,

(38) 1,2,3,4-tetrazin-5-yl,

(39) 1,2,4,5-tetrazin-4-yl,

(40) 1,3,4,5-tetrazin-2-yl,and

(41) 1,2,3,5-tetrazin-4-yl.

9. A compound according to claim 8 wherein the heteroaryl is selected from the group consisting of

(1) 3-isoxazolyl,

(2) 4-isoxazolyl,

(3) 5-isoxazolyl,

(4) 3-isothiazolyl,

(5) 4-isothiazolyl,

(6) 5-isothiazolyl,

(7) 2-oxazolyl,

(8) 4-oxazolyl,

(9) 5-oxazolyl,

(10) 2-thiazolyl,

(11) 4-thiazolyl,

(12) 5-thiazolyl,

(13) 1,2,3-thiadiazol-4-yl,

(14) 1,2,3-thiadiazol-5-yl,

(15) 1,2,4-thiadiazol-3-yl,

(16) 1,2,4-thiadiazol-5-yl,

(17) 1,3,4-thiadiazol-2-yl,

(18) 1,2,5-thiadiazol-3-yl,

(19) 1,2,3-oxadiazol-4-yl,

(20) 1,2,3-oxadiazol-5-yl,

(21) 1,2,4-oxadiazol-3-yl,

(22) 1,2,4-oxadiazol-5-yl,

(23) 1,3,4-oxadiazol-2-yl,

(24) 1,2,5-oxadiazol-3-yl,

(25) 1,2-diazinyl,

(26) 1,3-diazinyl, and

(27) 1,4-diazinyl.

10. A compound according to claim 9 wherein the heteroaryl is selected from the group consisting of

(1) 3-isothiazolyl,

(2) 4-isothiazolyl,

(3) 5-isothiazolyl,

(4) 2-oxazolyl,

(5) 4-oxazolyl,

(6) 5-oxazolyl,

(7) 2-thiazolyl,

(8) 4-thiazolyl,

(9) 5-thiazolyl,

(10) 1,2-diazinyl,

(11) 1,3-diazinyl, and

(12) 1,4-diazinyl, and

wherein the substitutents are selected from the group consisting of

(1) hydrogen,

(2) fluoro or chloro,

(3) C.sub.1-3 alkoxy,

(4) C.sub.1-3 alkylthio,

(5) CN,

(6) C.sub.1-3 alkyl, and

(7) --C(R.sup.5)(R.sup.6)--OH,

wherein R.sup.5 and R.sup.6 are each independently hydrogen, methyl or ethyl.

11. A compound according to claim 10 wherein

R.sup.1 is selected from the group consisting of

(a) S(O).sub.2 CH.sub.3,

(b) S(O).sub.2 NH.sub.2,

(c) S(O)NHCH.sub.3, and

(d) S(O)NHNH.sub.2.

12. A compound according to claim 11 wherein the hetereooaryl is selected from the group consisting of

(1) 3-isothiazolyl,

(2) 4-isothiazolyl,

(3) 5-isothiazolyl,

(4) 2-oxazolyl,

(5) 4-oxazolyl,

(6) 5-oxazolyl,

(7) 2-thiazolyl,

(8) 4-thiazolyl,

(9) 5-thiazolyl,

(10) 1,2-diazinyl,

(11) 1,3-diazinyl, and

(12) 1,4-diazinyl, and

wherein the substitutents are selected from the group consisting of

(1) hydrogen,

(2) fluoro or chloro,

(3) methoxy,

(4) methylthio,

(5) CF.sub.3,

(6) methyl.

13. A compound according to claim 1 selected from

(1) 3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(2) 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone,

(3) 3-(3,4-trichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(4) 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone.

14. A compound which is

3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone,

(b) 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, or a pharmaceutically acceptable salt thereof.

15. A compound according to claim 1 selected from

(1) 3-(4-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(2) 3-(4-Fluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone,

(3) 3-(2,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(4) 3-(3,4-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(5) 3-(2,6-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(6) 3-(2,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(7) 3-(3,5-Difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(8) 3-(4-Bromophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(9) 3-(4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(10) 3-(4-Methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(11) 3-(Phenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(12) 3-(2-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(13) 3-(2-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone,

(14) 3-(2-Bromo-4-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone,

(15) 3-(4-Chloro-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone,

(16) 3-(3-Bromo-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone,

(17) 3-(3-Chlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(18) 3-(2-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone,

(19) 3-(2,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone,

(20) 3-(3,4-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone,

(21) 3-(2,6-Dichlorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(22) 3-(3-Chloro-4-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone,

(23) 3-(4-Trifluoromethylphenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone,

(24) 3-(3-Fluoro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(25) 3-(3-Chloro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(26) 3-(3-Fluoro-4-methoxyphenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(27) 3-(2-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(28) 3-(4-Methylthiophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone,

(29) 3-(3-Fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(30) 3-(2-Chloro-6-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone,

(31) 3-(3-Bromo-4-methylphenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone,

(32) 3-(4-Bromo-2-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone,

(33) 3-(3,4-Dibromophenyl)-4-(4-(methylsulfonyl)phenyl)-2(5H)-furanone,

(34) 3-(4-Chloro-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone,

(35) 3-(4-Bromo-3-fluorophenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone, an

(36) 3-(4-Bromo-2-chlorophenyl)-4-(4-(methylsulfonyl)phenyl)2-(5H)-furanone.

16. A compound according to claim 1 selected from

(1) 3-(3,4-Dichlorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone,

(2) 3-(3,4-Difluorophenyl)-4-(4-(aminosulfonyl)phenyl)-2-(5H)-furanone,

(3) 3-(3-Chloro-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)2-(5H)-furanone, a nd

(4) 3-(3-Bromo-4-methoxyphenyl)-4-(4-(aminosulfonyl)phenyl)2-(5H)-furanone.

17. A compound which is 3-phenyl-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone, or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition for treating an inflammatory disease susceptable to treatment with an non-steroidal anti-inflammatory agent comprising:

a non-toxic therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

19. A pharmaceutical composition for treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:

a non-toxic therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition for treating an inflammatory disease susceptable to treatment with an non-steroidal a-ntiinflammatory agent comprising:

a non-toxic therapeutically effective amount of a compound according to claim 17 and a pharmaceutically acceptable carrier.

21. A pharmaceutical composition for treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:

a non-toxic therapeutically effective amount of a compound according to claim 17 and a pharmaceutically acceptable carrier.

22. A method of treating an inflammatory disease susceptable to treatment with an non-steroidal anti-inflammatory agent comprising:

administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to claim 1 and a pharmaceutically acceptable carder.

23. A method of treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising:

administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to claim 1.

24. A method of treating an inflammatory disease susceptable to treatment with an non-steroidal anti-inflammatory agent comprising:

administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to claim 17 and a pharmaceutically acceptable carrier.

25. A method of treating cyclooxygenase mediated diseases advantageously treated by an active agent that selectively inhibits COX-2 in preference to COX-1 comprising: administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound according to claim 17.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc